Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was the recipient of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,650,854 shares, a growth of 53.8% from the July 31st total of 3,023,251 shares. Currently, 12.0% of the shares of the company are sold short. Based on an average daily volume of 910,050 shares, the days-to-cover ratio is currently 5.1 days.

In other Pacira Pharmaceuticals news, SVP Scott Braunstein sold 768 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total transaction of $33,269.76. Following the completion of the sale, the senior vice president now owns 9,982 shares of the company’s stock, valued at $432,420.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total value of $37,740.60. Following the sale, the director now directly owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The disclosure for this sale can be found here. Insiders have sold 42,913 shares of company stock valued at $1,628,016 in the last ninety days. Company insiders own 6.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in PCRX. Benjamin F. Edwards & Company Inc. increased its stake in Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after buying an additional 1,149 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $114,000. FNY Partners Fund LP purchased a new stake in Pacira Pharmaceuticals during the first quarter valued at about $136,000. Ameritas Investment Partners Inc. purchased a new stake in Pacira Pharmaceuticals during the first quarter valued at about $144,000. Finally, Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after buying an additional 1,752 shares during the period.

A number of equities research analysts have issued reports on PCRX shares. Wedbush reaffirmed an “outperform” rating and set a $87.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 21st. Canaccord Genuity reissued a “buy” rating and issued a $60.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, May 15th. BidaskClub raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Mizuho reissued a “buy” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Royal Bank Of Canada set a $58.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $53.31.

Pacira Pharmaceuticals (PCRX) opened at 38.00 on Friday. Pacira Pharmaceuticals has a 12 month low of $29.95 and a 12 month high of $58.95. The company’s market capitalization is $1.53 billion. The company has a 50-day moving average price of $39.71 and a 200 day moving average price of $44.89.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.21 earnings per share. On average, equities research analysts forecast that Pacira Pharmaceuticals will post ($0.16) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Short Interest Update” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/pacira-pharmaceuticals-inc-pcrx-short-interest-update/1537286.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.